Abbvie Inc Stock Price, News & Analysis

AbbVie has announced promising results from a Phase 2 trial of navitoclax combined with ruxolitinib for myelofibrosis, a challenging blood cancer. The exploratory analysis included 34 patients, with a 100% survival estimate for those showing grade improvement in bone marrow fibrosis after over two years. Importantly, 38% of patients had a significant improvement in fibrosis, while 23% showed a reduction in variant allele frequency. Presented at AACR 2022, these findings support ongoing Phase 3 studies and suggest navitoclax may enhance patient outcomes in myelofibrosis.

AbbVie announced positive results from the Phase 3 VIRGO trial, evaluating the investigational twice-daily administration of VUITY, an eye drop for presbyopia. The study demonstrated significant improvement in near vision without compromising distance vision. A total of 230 participants were involved, with results indicating that participants gained three lines or more in near visual acuity at Day 14. These findings will support a supplemental New Drug Application to the FDA in Q2 2022. While VUITY is FDA-approved for once-daily use, twice-daily administration is not yet approved.

Allergan Aesthetics, part of AbbVie (NYSE: ABBV), has entered a groundbreaking partnership with Resorts World Las Vegas to become the preferred aesthetics and rewards partner at the resort. This multiyear agreement grants Allergan exclusive branding rights to the Allē Lounge on 66 and the Allē Backstage space at the Resorts World Theatre. The partnership aims to enhance consumer engagement and introduce millions of visitors to Allergan’s product portfolio. This marks Allergan's first branding of a dedicated area at a major resort.

AbbVie (NYSE: ABBV) will present 30 abstracts at the 2022 American Academy of Neurology Annual Meeting, showcasing its leadership in neuroscience. Key highlights include ongoing research on migraine treatments, particularly the newest migraine medicine, atogepant (QULIPTA™), and advancements in therapies for advanced Parkinson's disease. Notable studies will also focus on spasticity and cervical dystonia with data on onabotulinumtoxinA (BOTOX®). The meeting will take place in Seattle from April 2-7, 2022, with virtual presentations from April 24-26.

AbbVie and Allergan Aesthetics will present 12 abstracts and two late-breaking presentations at the 2022 AAD Annual Meeting, showcasing their commitment to dermatologic research. Key highlights include new findings on RINVOQ® and SKYRIZI® in treating atopic dermatitis and psoriasis. Notably, a post-hoc analysis indicates RINVOQ's superior efficacy compared to DUPIXENT® in moderate to severe atopic dermatitis. Allergan will introduce a novel hydrating serum and present data on HA injectable gel for jawline definition. These presentations emphasize the companies' dedication to enhancing patient care in dermatology.

AbbVie announced that the FDA approved RINVOQ (upadacitinib) for treating adults with moderately to severely active ulcerative colitis (UC) who have not adequately responded to TNF blockers. This indicates AbbVie's expansion into gastroenterology with RINVOQ now approved for four indications. In clinical trials, RINVOQ showed higher rates of clinical remission and response, achieving significant outcomes at weeks 8 and 52 compared to placebo. The treatment may cause serious side effects, including infections and cardiovascular risks, warranting careful patient monitoring.

AbbVie announced that LASTACAFT (alcaftadine ophthalmic solution 0.25%) is now available over-the-counter, previously requiring a prescription. This antihistamine eye drop provides relief from itchy allergy eyes caused by seasonal and year-round allergens, working within three minutes and lasting for 16 hours. With an estimated 40% of Americans affected by ocular allergies, this move expands AbbVie's retail eye drop portfolio, alongside the REFRESH product line. LASTACAFT is available in a 5 mL bottle with a 60-day supply or a twin pack for 120 days, enhancing accessibility for allergy sufferers.

AbbVie and Scripps Research have announced a global collaboration to develop new antiviral treatments for COVID-19, aimed at addressing the evolving needs due to new virus variants. The partnership leverages Scripps' expertise and resources, with initial funding support from the Bill & Melinda Gates Foundation. This initiative represents AbbVie's commitment to enhancing access to innovative oral antiviral treatments. The collaboration's success hinges on regulatory approvals and customary closing conditions.